Medigene AG: Medigene presents approaches for improving selection of neoantigens for use in cancer immunotherapy
- Automated in vitro testing could reveal better neoantigens that activate more effective killer T cell responses - Two…
- Automated in vitro testing could reveal better neoantigens that activate more effective killer T cell responses - Two…
. - Automatisiertes in vitro Testverfahren könnte bessere Neoantigene zur Aktivierung von mehr Killer-T-Zellen auffinden…
Growing revenues from core business immunotherapies, clinical trial application for second immunotherapy submitted, fina…
Medigene AG (FSE: MDG1, Prime Standard, TecDAX) announced that researchers from Oslo University Hospital presented an up…
Die Medigene AG (FWB: MDG1, Prime Standard, TecDAX) gibt bekannt, dass Wissenschaftler des Universitätskrankenhauses Os…
Medigene AG (FWB: MDG1, Prime Standard, TecDAX) today announced its participation at six upcoming scientific and investo…
Die Medigene AG (FWB: MDG1, Prime Standard, TecDAX) gibt ihre Teilnahme an sechs bevorstehenden Wissenschafts- und Inves…
Medigene AG (FSE: MDG1, Prime Standard, TecDAX) announced today that it has granted an exclusive, worldwide license for…
Prof. Dolores Schendel, CEO and CSO of Medigene AG (MDG1, Frankfurt, Prime Standard), will present a new approach to dev…
Medigene AG (MDG1, Frankfurt, Prime Standard), a clinical stage immuno-oncology company focusing on the development of T…